The investigation of transcriptional control of NTF genes in PD appears to be warranted, as pharmacokinetic studies in rodents suggest a long half-lives for both GDNF and NTRN, following single brain infusions [292] (making it less likely that continuous transgene expression is necessary). This evidence concerns the gene GDNF and Parkinson disease.